. Author manuscript; available in PMC: 2015 Jun 5.

Published in final edited form as: Crit Rev Toxicol. 2013 Sep;43(8):611–631. doi: 10.3109/10408444.2013.822844

Table 3.

Concordance between genetically modified assays, the NTP bioassays and human evaluations.

Model	Positive	Negative	Overall
Concordance with NTP mouse carcinogens
Trp53⁺^/⁻	7/20 (35%)	10/10 (100%)	17/30 (57%)
Tg.AC	12/23 (52%)	8/10 (80%)	20/33 (61%)
rasH2	16/20 (80%)	7/8 (88%)	23/28 (82%)
Concordance with trans-species mouse and rat carcinogens
Trp53⁺^/⁻	5/14 (36%)	9/9 (100%)	14/23 (61%)
Tg.AC	7/14 (50%)	8/10 (80%)	15/24 (63%)
rasH2	14/16 (88%)	7/8 (88%)	21/24 (88%)
Concordance with known or likely human carcinogens
Trp53⁺^/⁻	6/14 (43%)
Tg.AC	8/12 (67%)
rasH2	12/14 (86%)